Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Personalis Establishes UK Subsidiary and Appoints Mark Dronsfield as Director of European Sales

Published: Wednesday, September 25, 2013
Last Updated: Wednesday, September 25, 2013
Bookmark and Share
Personalis announced the formation of its UK subsidiary, Personalis UK Limited, to better serve the needs of customers across Europe.

The company also announced the appointment of Mark Dronsfield, Ph.D., as Director of European Sales.

“Given the expanding research and clinical demands for large scale exome and genome analysis, we felt it was important to augment our presence in the European markets,” said Personalis CEO John West.  “We wanted to be prepared to build infrastructure on both the commercial and operational sides, so we are best able to address the needs of researchers and clinicians.”

West continued, “We are especially pleased to open our UK subsidiary as two of our major investors, Abingworth Management LLP and Dr. Herman Hauser, FRS, are UK-based.” Both Abingworth and Dr. Hauser’s Amadeus venture fund were investors in Solexa, Ltd, inventor of the sequencing-by-synthesis technology at the core of Illumina’s sequencing systems today. Abingworth’s Dr. Jonathan MacQuitty currently serves as Personalis’ Chairman.

Initially, Personalis intends to build out its commercial team, but will also build services infrastructure in the UK as customers’ needs require.

Mark Dronsfield, Personalis’ newly appointed Director of European Sales, was most recently Head of Commercial Operations Europe for RainDance Technologies and has also held European commercial operations positions for Illumina, Affymetrix and Life Technologies.

“We believe that the combination of Personalis’ deep expertise in exome/genome sequencing and analysis, along with a direct presence in Europe, will open many new opportunities as the clinical demand for next generation sequencing rapidly grows,” said Dronsfield.  “I am really excited to be part of Personalis’ European expansion.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!